– USA, MA – Lantheus Holdings, Inc. (NASDAQ: LNTH), today announced the appointment of Minnie Baylor-Henry to its Board as an Independent Director, effective immediately, bringing the Board to nine members, of whom eight are independent.
“We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law and regulation, to the Lantheus Board. As we continue to build value for shareholders through the execution of our strategy, Minnie’s deep experience in this industry and specifically her regulatory insight will be invaluable. As Lantheus executes on its purpose to find, fight and follow disease to improve patient outcomes, leveraging her vast experience will be critical to the long-term success of our mission,” said Board Chairman, Brian Markison.
Ms. Baylor-Henry will also join the Compensation Committee and the Science and Technology Committee.
About Minnie Baylor-Henry, Esq.,
Ms. Baylor-Henry is the President of B-Henry & Associates, a consulting firm focused on providing regulatory and compliance strategy services to life sciences companies. Before assuming her current role, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson’s Medical Devices & Diagnostics business where she was directly responsible for coordinating the regulatory strategy for the approval of a wide portfolio of products globally. Before that Ms. Baylor-Henry was a National Director for Regulatory & Capital Markets Consulting at Deloitte & Touche. From 1991-1999, she worked at the U.S. Food & Drug Administration where she served in many roles, most notably, FDA’s National Health Fraud Coordinator and, within the Center for Drugs, as the Director of the Division of Drug Marketing, Advertising, and Communications. In addition, Ms. Baylor-Henry is a former President & Board Chair of the Drug Information Association and the Food and Drug Law Institute.
“I am honored to join the Lantheus Board and work alongside such an accomplished group to help guide the future endeavors of the Company,” commented Ms. Baylor-Henry. “With its strong executive team and a clear vision for the future, I believe that Lantheus is well-positioned to continue to deliver on its mission to improve patient outcomes while achieving steady growth.”
Ms. Baylor-Henry is currently an independent director of Apyx Medical (NASDAQ: APYX), Paratek Pharmaceuticals (NASDAQ: PRTK), and scPharmaceuticals (NASDAQ: SCPH). Ms. Baylor-Henry is also a member of the Board of Directors of several not-for-profit companies, including Mass Eye & Ear Hospital and Dress for Success Boston. Ms. Baylor-Henry received her Pharmacy degree from Howard University’s College of Pharmacy and her law degree from Catholic University’s Columbus School of Law.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find Fight and Follow serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI, an artificial intelligence platform that assists in the evaluation of PSMA PET images; TechneLite (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA for the treatment of certain rare neuroendocrine tumors; and RELISTOR for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New Jersey, Canada, and Sweden.
For more information: https://www.lantheus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
